The news is by your side.


Novartis hopeful for novel heart drug, despite ‘modest’ benefit

ZURICH: Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine‚Äôs limited benefits. Keenly awaited clinical trial results released on Sunday showed heart-attack survivors on one of three doses of canakinumab were 15 percent less likely to suffer another major cardiac event than those on a placebo. Novartis had said in June that the drug met its goal in the study but details were only…